Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
144 hedge funds and large institutions have $2.47B invested in Ra Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 49 increasing their positions, 47 reducing their positions, and 33 closing their positions.
120% more funds holding in top 10
Funds holding in top 10: 5 → 11 (+6)
7% more capital invested
Capital invested by funds: $2.31B → $2.47B (+$161M)
4% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 47
3% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 33
1% less funds holding
Funds holding: 146 → 144 (-2)
88% less call options, than puts
Call options by funds: $3.53M | Put options by funds: $30.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
HBK Investments
Dallas,
Texas
|
+$89.4M |
| 2 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$53.7M |
| 3 |
Barclays
London,
United Kingdom
|
+$43.5M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$37.6M |
| 5 |
TAL
TIG Advisors LLC
New York
|
+$36.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$71.3M |
| 2 |
Citigroup
New York
|
-$46.1M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$35.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$34.9M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$33.3M |
RARX Hedge Fund Activity: Q1 2020 in Review
144 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q1 2020, worth a combined $2.47B — up 7% from $2.31B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new RARX positions and 33 closed out — a net gain of 1 holder — while 49 added to existing stakes and 47 trimmed.
The largest buyer was HBK Investments, adding an estimated $89.4M. The largest seller was Deerfield Management, exiting entirely with an estimated $71.3M sold.
- 144 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q1 2020, down from 146 in Q4 2019.
- Funds reported $2.47B of Ra Pharmaceuticals, Inc. Common Stock stock for Q1 2020, up 7% quarter-over-quarter.
- 34 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 33 closed out, a net change of +1 holder.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was HBK Investments, an estimated $89.4M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was Deerfield Management, an estimated $71.3M sold.
Based on aggregated 13F filings for Q1 2020.